| |
| |
| |
| |
Publications |
| |
Improving Early Prostate Cancer Diagnosis
Egenix has developed a blood test for the early diagnosis of prostate cancer in collaboration with the University of Beijing (Beijing, China). The Company's innovative approach to measurement of complex PSA (prostate specific antigen) will substantially improve the specificity of screening for the early diagnosis of prostate cancer.
Our diagnostic, PACT, is a novel screening test for prostate cancer. Egenix developed this novel sandwich ELISA immunoassay in partnership with the Institute of Urology Peking University (“University of Beijing”). Data from the first 288 clinical samples tested in two separate clinical evaluations (one in China and one in the US) showed a specificity of greater than 65% at a sensitivity of 90%. At this threshold, unnecessary biopsies (versus PSA) could be reduced by two-thirds.
Egenix’ complex PSA test more than doubles the specificity of current versions of the complex PSA test and improves the accuracy of testing for early diagnosis of prostate cancer. We are in the process of blindly testing 750 samples (one-third each prostate cancer, BPH, and prostate cancer-disease free) at the University of Colorado at Denver Health Sciences Center. We expect to run the samples by the end of July and could be in a position to move forward with licensing discussions shortly thereafter.